Abstract Number: 594 • 2016 ACR/ARHP Annual Meeting
Maintenance of Improvements in Patients’ Physical Function, Workplace and Household Productivity, and Reduction in Caregiver Burden with 2 Years of Certolizumab Pegol Treatment in DMARD-Naive, Early RA Patients with Severe Progressive Disease
Background/Purpose: Rheumatoid arthritis (RA) is associated with loss of physical function, work disability, and decreased quality of life. Early treatment with certolizumab pegol (CZP) in…Abstract Number: 2262 • 2016 ACR/ARHP Annual Meeting
CR6086 a New Potent EP4 Receptor Antagonist with Immunomodulatory Activities
Background/Purpose: In the early phase of rheumatoid arthritis (RA), PGE2 recruits different immune cells from the blood stream into target tissues. Via the EP4 receptor,…Abstract Number: 519 • 2015 ACR/ARHP Annual Meeting
In Indigenous North Americans at High Risk for RA Complement C5 Level Is Associated with ACPA Positivity and C5a with Transition to Synovitis Even after Correcting for in Vitro Complement Activation Found with Prolonged Sample Storage
Background/Purpose: Complement activation, a key component of innate immunity and activator of adaptive immunity has been linked to RA pathogenesis. Anti-citrullinated peptide antibody (ACPA) and…Abstract Number: 1638 • 2015 ACR/ARHP Annual Meeting
Early Response As a Predictor of Long-Term Remission in DMARD-Naïve Patients with Severe, Active and Progressive Rheumatoid Arthritis Treated with Certolizumab Pegol in Combination with Methotrexate
Background/Purpose: In established rheumatoid arthritis (RA), a lack of response to treatment with certolizumab pegol (CZP) at early timepoints is associated with a low probability…Abstract Number: 2741 • 2015 ACR/ARHP Annual Meeting
An Analysis of the Efficacy of Tofacitinib Monotherapy in MTX-Naïve Patients with Early RA Compared with Patients with Established RA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. In a Phase 3 study (ORAL Start; NCT01039688), tofacitinib monotherapy in MTX-naïve…Abstract Number: 539 • 2015 ACR/ARHP Annual Meeting
Quantification of T-Cell Receptor Excision Circles (TREC) from Peripheral Blood in Patients with Inflammatory Polyarthritis of Recent Onset (EPA): Association with Radiographic Joint Damage
Background/Purpose: Patients with established Rheumatoid arthritis (RA) present evidence for an exhausted immune system. It is not known whether patients seen at the Early inflammatory…Abstract Number: 1644 • 2015 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data 3 (RAPID3)-Defined Remission Is As Stringent As ACR/EULAR Boolean-Defined Remission in a Clinical Trial of Patients with Early Rheumatoid Arthritis Treated with Abatacept
Background/Purpose: Routine Assessment of Patient Index Data 3 (RAPID3) comprises the three patient-reported ACR RA Core Data Set measures: function (HAQ-DI), pain and patient global…Abstract Number: 2748 • 2015 ACR/ARHP Annual Meeting
Evaluation of Patient-Reported Outcomes By Baseline Disease Duration: 6-Month Data from Two Clinical Trials of Patients with Early Rheumatoid Arthritis Treated with Abatacept
Background/Purpose: Patients with RA and longer disease duration generally do not respond as well to treatment with DMARDs as patients with shorter duration of disease.…Abstract Number: 541 • 2015 ACR/ARHP Annual Meeting
Microrna-125b Expression in PBMCs Is Associated with Disease Activity in Patients with Early Rheumatoid Arthritis
Background/Purpose: MicroRNAs (miRNAs) are small non-coding RNAs that function as negative regulators of gene expression at posttranscription level and play a significant role in rheumatoid…Abstract Number: 1662 • 2015 ACR/ARHP Annual Meeting
Treat to Target of Remission Is Effective but Not All Patients Are Always in Remission
Background/Purpose: Presently the goals of rheumatoid arthritis (RA) therapy are to control symptoms, to prevent joint damage and disability. Attaining long-term clinical remission or at…Abstract Number: 3172 • 2015 ACR/ARHP Annual Meeting
Effect of Anti Citrullinated Protein Antibodies on Periarticular and Systemic Bone Mass in Early Arthritis Patients
Background/Purpose: Recently it has been described that anti citrullinated protein antibodies (ACPA) can induce differentatiomn and activation of osteoclasts even before arthritis onset (1,2). The…Abstract Number: 546 • 2015 ACR/ARHP Annual Meeting
Adipokines and Insulin-like Growth Factor 1 As Predictors of Clinical and Radiographic Outcomes in Early Rheumatoid Arthritis
Background/Purpose: Adipokines are cytokines/hormones primarily synthesized in white adipose tissue. In rheumatoid arthritis (RA), some adipokines have been associated with worse outcomes (1-3). The aim…Abstract Number: 1669 • 2015 ACR/ARHP Annual Meeting
Serum Survivin Predicts Responses to Treatment in Active Rheumatoid Arthritis
Background/Purpose: Survivin is an oncological biomarker. In rheumatoid arthritis (RA), elevated serum survivin is common and has been used to predict disease onset and progressive…Abstract Number: 3242 • 2015 ACR/ARHP Annual Meeting
A Comprehensive Method for Using Sensewear MiniTM Monitors to Explore Differences in Ambulatory Activities in People Living with and without Early Rheumatoid Arthritis: Moving Beyond Measuring Total Steps
Background/Purpose: Measures of daily steps does not allow for examination of how steps are accumulated from different type or intensity of ambulatory activity, which is…Abstract Number: 556 • 2015 ACR/ARHP Annual Meeting
Induction-Maintenance in Early RA: A Meta-Analysis of Trials Using MTX Plus Adalimumab As Induction Therapy
Background/Purpose: The goal of rheumatoid arthritis (RA) treatment is remission or, when not achievable, low-disease-activity (LDA). Initial combined therapy with MTX + anti-TNF achieves these…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 18
- Next Page »